Atlas Trials

TTR-mediated Amyloidosis

8 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch TTR-mediated Amyloidosis

RecordFirmDate
A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis (NCT02292186)Alnylam Pharmaceuticals2014-10-01
Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis (NCT01981837)Alnylam Pharmaceuticals2013-12-01
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (NCT01960348)Alnylam Pharmaceuticals2013-11-01
The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran) (NCT01961921)Alnylam Pharmaceuticals2013-10-01
A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers (NCT01814839)Alnylam Pharmaceuticals2013-03-01
Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis (NCT01617967)Alnylam Pharmaceuticals2012-05-01
Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects (NCT01559077)Alnylam Pharmaceuticals2012-03-01
Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR) (NCT02939820)Alnylam Pharmaceuticals

Track TTR-mediated Amyloidosis automatically

Every clearance here is in the API, with alerts when new ones post.